Ποια είναι η τιμή για Hybio Pharmaceutical Co., Ltd. (300199)

Η τιμή για Hybio Pharmaceutical Co., Ltd. (300199) είναι $3.32

Ποια είναι η κεφαλαιοποίηση αγοράς για Hybio Pharmaceutical Co., Ltd. (300199)

Η κεφαλαιοποίηση αγοράς για Hybio Pharmaceutical Co., Ltd. (300199) είναι $2.93B

Hybio Pharmaceutical Co., Ltd. (300199) Τιμή και Κεφαλαιοποίηση Αγοράς

Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.

Η τιμή για 300199	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$5,760.45 $2.93B	NVDA	$5.088T	+173,636.09%
$5,241.02 $2.93B	AAPL	$4.629T	+157,970.19%
$4,661.91 $2.93B	GOOG	$4.118T	+140,504.03%
$4,174.07 $2.93B	MSFT	$3.687T	+125,790.73%
$3,169.74 $2.93B	AMZN	$2.800T	+95,499.86%

Η τιμή για 300199

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$5,760.45 $2.93B